Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
F305092-50mg | 50mg | In stock | $14.90 | |
F305092-250mg | 250mg | In stock | $61.90 | |
F305092-1g | 1g | In stock | $205.90 | |
F305092-5g | 5g | In stock | $815.90 |
Synonyms | BRD-K88025533-003-01-7 | GTPL2407 | C19H33NO2 | CS-0030669 | FINGOLIMOD [VANDF] | FINGOLIMOD (MART.) | STL445699 | BCP05969 | D10001 | Fingolimod | FINGOLIMOD [WHO-DD] | FINGOLIMOD [MI] | Fty-720 | DB08868 | KKGQTZUTZRNORY-UHFFFAOYSA-N | 2-Amino-2-[2-(4-o |
---|---|
Specifications & Purity | Moligand™, ≥97% |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | ACTIVATOR, AGONIST, CHANNEL BLOCKER |
Mechanism of action | Activator of K ir3.4;Agonist of S1P 1 receptor;Agonist of S1P 5 receptor;Channel blocker of TRPM7 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Pubchem Sid | 488187419 |
---|---|
Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/488187419 |
IUPAC Name | 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
INCHI | InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3 |
InChi Key | KKGQTZUTZRNORY-UHFFFAOYSA-N |
Canonical SMILES | CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N |
Isomeric SMILES | CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N |
PubChem CID | 107970 |
Molecular Weight | 307.47 |
PubChem CID | 107970 |
---|---|
ChEBI | CHEBI:63115 |
ChEMBL Ligand | CHEMBL314854 |
Wikipedia | Fingolimod |
BindingDB Ligand | 50158336 |
CAS Registry No. | 162359-55-9 |
DrugBank Ligand | DB08868 |
PEP | fingolimod |
Reactome Reaction | R-HSA-9678854 |
Reactome Drug | R-ALL-9678808 |
DrugCentral Ligand | 4167 |
GPCRdb Ligand | fingolimod |
PubChem SID | 488187419 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
B2208457 | Certificate of Analysis | Dec 12, 2024 | F305092 |
B2208464 | Certificate of Analysis | Dec 12, 2024 | F305092 |
D2314605 | Certificate of Analysis | Feb 13, 2023 | F305092 |
D2314611 | Certificate of Analysis | Feb 13, 2023 | F305092 |
D2314612 | Certificate of Analysis | Feb 13, 2023 | F305092 |
D2314629 | Certificate of Analysis | Feb 13, 2023 | F305092 |
D2314656 | Certificate of Analysis | Feb 13, 2023 | F305092 |
I2410144 | Certificate of Analysis | Feb 13, 2023 | F305092 |
B2208202 | Certificate of Analysis | Nov 11, 2021 | F305092 |
B2208329 | Certificate of Analysis | Nov 11, 2021 | F305092 |
Solubility | Chloroform (Very Slightly, Heated), DMSO (Slightly, Heated), Methanol (Slightly) |
---|---|
Melt Point(°C) | 123-125ºC |
1. Linghong Huang, Sufen Peng, Zonghua Liu, Juncheng Zhang, Ning Liu, Jiansheng Lin. (2022) Natural blood plasma-based hydrogels as tumor vaccines delivery systems to enhance biomimetic recruitment of antigen presenting cells for tumor immunotherapy. Materials Today Bio, 17 (100497). [PMID:36420056] [10.1016/j.mtbio.2022.100497] |
1. Horga A, Montalban X. (2008) FTY720 (fingolimod) for relapsing multiple sclerosis.. Expert Rev Neurother, 8 (5): (699-714). [PMID:18457527] [10.1021/op500134e] |
2. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C et al.. (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists.. Science, 296 (5566): (346-9). [PMID:11923495] [10.1021/op500134e] |
3. Sanna MG, Liao J, Jo E, Alfonso C, Ahn MY, Peterson MS, Webb B, Lefebvre S, Chun J, Gray N et al.. (2004) Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate.. J Biol Chem, 279 (14): (13839-48). [PMID:14732717] [10.1021/op500134e] |
4. Forrest M, Sun SY, Hajdu R, Bergstrom J, Card D, Doherty G, Hale J, Keohane C, Meyers C, Milligan J et al.. (2004) Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes.. J Pharmacol Exp Ther, 309 (2): (758-68). [PMID:14747617] [10.1021/op500134e] |
5. Hale JJ, Lynch CL, Neway W, Mills SG, Hajdu R, Keohane CA, Rosenbach MJ, Milligan JA, Shei GJ, Parent SA et al.. (2004) A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.. J Med Chem, 47 (27): (6662-5). [PMID:15615513] [10.1021/op500134e] |
6. Cohen JA, Chun J. (2011) Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.. Ann Neurol, 69 (5): (759-77). [PMID:21520239] [10.1021/op500134e] |
7. Teymouri S, Pourbayram Kaleybar S, Hejazian SS, Hejazian SM, Ansarin K, Ardalan M, Zununi Vahed S. (2023) The effect of Fingolimod on patients with moderate to severe COVID-19.. Pharmacol Res Perspect, 11 (1): (e01039). [PMID:36567519] [10.1021/op500134e] |
8. Demont EH, Bailey JM, Bit RA, Brown JA, Campbell CA, Deeks N, Dowell SJ, Eldred C, Gaskin P, Gray JR et al.. (2016) Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral Doses.. J Med Chem, 59 (3): (1003-20). [PMID:26751273] [10.1021/op500134e] |
9. Linghong Huang, Sufen Peng, Zonghua Liu, Juncheng Zhang, Ning Liu, Jiansheng Lin. (2022) Natural blood plasma-based hydrogels as tumor vaccines delivery systems to enhance biomimetic recruitment of antigen presenting cells for tumor immunotherapy. Materials Today Bio, 17 (100497). [PMID:36420056] [10.1016/j.mtbio.2022.100497] |